- Condition
- Knee Osteoarthritis
- Patient profile
- F, age band 55–64, United Kingdom
- Outcome scale
- WOMAC (lower is better)
Twelve-month structured follow-up of a UK patient with grade III bilateral knee osteoarthritis, tracked on the WOMAC Index after a Wharton's Jelly MSC program in Istanbul.
This is one patient's tracked outcome. Knee osteoarthritis response to MSC therapy varies with Kellgren-Lawrence grade, BMI, prior surgeries, and baseline function. This case is not a predictor of any other patient's outcome.
WOMAC timeline
WOMAC scores combine pain, stiffness, and physical function subscales. 0 = no symptoms; 96 = maximal symptoms. A change of ≥12 points is generally considered clinically meaningful in knee OA literature.
| Timepoint | WOMAC | Δ vs baseline |
|---|---|---|
| Baseline | 64 | — |
| Day 30 | 58 | -6 |
| Day 90 | 41 | -23 |
| Day 180 | 33 | -31 |
| Day 365 | 31 | -33 |
Bilateral grade III knee osteoarthritis on Kellgren-Lawrence grading, with 6 years of symptomatic progression. Patient was using daily NSAIDs (washed out 14 days before infusion), reported night pain interfering with sleep 4–5 nights per week, and walking tolerance under 400 metres.
Intravenous Wharton's Jelly MSCs delivered as a single infusion alongside ultrasound-guided bilateral intra-articular MSC injection. Total program duration in Istanbul: 4 days. Pre-procedure workup included MRI review, CBC, CMP, hsCRP, ESR, vitamin D and HbA1c.
Structured WOMAC capture at Days 30, 90, 180 and 365 via the patient coordinator. Largest improvement observed between Days 30 and 90 (Δ −17 points). Walking tolerance at Day 180 self-reported at 1.4 km without rest. Night pain reduced to 1 night per week or fewer at Day 180 and maintained at Day 365.
Mild transient knee soreness for 48 hours post intra-articular injection. No infection. No systemic adverse events. None reported through Day 365.